GlucoTrack Inc (GCTK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GlucoTrack Inc (GCTK) has a cash flow conversion efficiency ratio of -1.392x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.94 Million) by net assets ($2.83 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GlucoTrack Inc balance sheet quality to measure how much of total assets are equity-financed.
GlucoTrack Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how GlucoTrack Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check GCTK cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
GlucoTrack Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GlucoTrack Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Altai Resources Inc.
V:ATI
|
-0.051x |
|
Prosper Gold Corp.
V:PGX
|
-0.028x |
|
Gaming Realms plc
LSE:GMR
|
0.246x |
|
Blockchaink2 Corp
V:BITK
|
0.129x |
|
Anpario Plc
LSE:ANP
|
0.112x |
|
Imalliance SA
PA:MLIML
|
N/A |
|
Octopus Aim Vct Plc
LSE:OOA
|
-0.006x |
|
Aurora Solar Technologies Inc
V:ACU
|
0.477x |
Annual Cash Flow Conversion Efficiency for GlucoTrack Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of GlucoTrack Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see GlucoTrack Inc (GCTK) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.83 Million | $-15.24 Million | -5.389x | -660.90% |
| 2024-12-31 | $-13.00 Million | $-12.49 Million | 0.961x | +146.84% |
| 2023-12-31 | $3.20 Million | $-6.56 Million | -2.051x | +32.34% |
| 2022-12-31 | $1.23 Million | $-3.73 Million | -3.032x | -314.66% |
| 2021-12-31 | $5.16 Million | $-3.77 Million | -0.731x | -87.58% |
| 2020-12-31 | $8.98 Million | $-3.50 Million | -0.390x | -114.12% |
| 2019-12-31 | $-1.41 Million | $-3.90 Million | 2.761x | +62.18% |
| 2018-12-31 | $-2.87 Million | $-4.89 Million | 1.703x | +378.73% |
| 2017-12-31 | $-16.57 Million | $-5.90 Million | 0.356x | -26.69% |
| 2016-12-31 | $-10.95 Million | $-5.31 Million | 0.485x | -25.92% |
| 2015-12-31 | $-6.97 Million | $-4.57 Million | 0.655x | -5.86% |
| 2014-12-31 | $-4.83 Million | $-3.36 Million | 0.696x | +139.18% |
| 2013-12-31 | $-11.06 Million | $-3.22 Million | 0.291x | -93.63% |
| 2012-12-31 | $-503.07K | $-2.30 Million | 4.566x | +330.72% |
| 2011-12-31 | $968.24K | $-1.92 Million | -1.979x | -- |
About GlucoTrack Inc
GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications… Read more